Mumbai, July 26, 2017: Pharma Major, Wockhardt has received final approval from United States Food and Drug Administration (USFDA) for its ANDA for 0.1 percent ophthalmic solution of Olopatadine HCI. Olopatadine HCl eye drops used for the treatment of opthalmic allergies, company said in a filing with BSE The eye drop Olopatadine HCI 0.1 percent ophthalmic solution is a generic version of Patanol, marketed at US by Alcon, a subsidiary of Novartis. The product will be manufactured at USFDA approved contract manufacturing organization based in Montreal, Canada.
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…